Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 456

The DOI matches its Crossref record.

Effects of 22 Months of Treatment with Inhaled Corticosteroids and/or Beta-2-Agonists on Lung Function, Airway Responsiveness, and Symptoms in Children with Asthma

Van Essen-Zandvliet, Elisabeth E., Hughes, Michael D., Waalkens, Herman J., Duiverman, Eric J., Pocock, Stuart J., Kerrebijn, Karel F., The Dutch Chronic Non-Specific Lung Disease Study Group·1992·American Review of Respiratory Disease

Abstract

Abstract In a randomized double-blind multicenter clinical study, 116 children with asthma were randomly assigned to treatment with an inhaled beta-2-agonist (salbutamol 0.2 mg) plus an inhaled corticosteroid (budesonide 0.2 mg) three times a day (BA + CS) or to an inhaled beta-2-agonlst (salbutamol 0.2 mg) plus a placebo three times a day (BA + PL). After a median follow-up time of 22 months, 26 patients receiving BA + PL (45%) had withdrawn from randomized treatment, mainly because of asthma symptoms, compared with three withdrawals in the patients receiving BA + CS (p < 0.0001). The FEV1, expressed as a percentage of the predicted value for age, sex, and height, showed an absolute increase of 7.0% after 2 months of BA + CS compared with a decrease of 4.0% after 2 months of BA + PL. This 11% difference in percent predicted FEV1 (95% confidence interval, 7 to 15%; p < 0.0001) was then maintained after a median follow-up period of 22 months. Postbronchodilator FEV1 showed an absolute increase of 3.7% predicted within 2 months in patients receiving BA + CS and an absolute decrease of 1.1% predicted in children receiving BA + PL (p = 0.0005). Thereafter, this difference between the two treatment groups was maintained. Average peak expiratory flow rate (PEFR) increased from baseline by 36.6 L/min in the BA + CS group compared with 3.7 L/min in the BA + PL group (p = 0.003). This difference then remained for the median follow-up time of 22 months. Mean airway responsiveness expressed as the provocative dose of histamine required to give a 20% fall in FEV1 increased from baseline to 4 months by 0.98 doubling doses in children receiving BA + CS compared with a decrease of 0.42 doubling doses in patients receiving BA + PL. This represents a difference of 1.4 doubling dose (95% confidence interval, 0.77 to 2.02; p < 0.0001), which became even greater with further follow-up and did not reach a plateau after the median follow-up period of 22 months. PEFR-variability expressed as the average standard deviation of daily measurements was reduced by 5.9 L/min within 2 months in patients receiving BA + CS (nearly one-quarter in relative terms) compared with an increase of 1.6 L/min in those receiving BA + PL (p = 0.015). Thereafter, the difference was maintained. After 2 months of treatment the median number of days with symptoms remained 3 days per 2-wk period in the BA + PL group and decreased to 2 days in the BA + CS group. This difference increased to 3 days versus 1 day at 12 months (p = 0.016) and 4 days versus zero days after 22 months (p = 0.25). No serious side effects have been reported in either treatment group. This study provides strong evidence that inhaled corticosteroids are important in the long-term treatment of childhood asthma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/ajrccm/146.3.547

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 456

Metadata

Authors
Van Essen-Zandvliet, E. E., Hughes, M. D., Waalkens, H. J., Duiverman, E. J., Pocock, S. J., Kerrebijn, K. F., & The Dutch Chronic Non-Specific Lung Disease Study Group
Venue
American Review of Respiratory Disease
Published
1992-09
Volume
146
Issue
3
Pages
547-554
ISSN
0003-0805 (ISSN-L)
OpenAlex
W2139129119
Cited by
456
References
0
FWCI
9.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of 22 Months of Treatment with Inhaled Corticosteroids and/or Beta-2-Agonists on Lung Function, Airway Responsiveness, and Symptoms in Children with Asthma. https://app.cochat.ai/papers/10.1164/ajrccm/146.3.547
The paper
Van Essen-Zandvliet, E. E., Hughes, M. D., Waalkens, H. J., Duiverman, E. J., Pocock, S. J., Kerrebijn, K. F., & The Dutch Chronic Non-Specific Lung Disease Study Group. (1992). Effects of 22 Months of Treatment with Inhaled Corticosteroids and/or Beta-2-Agonists on Lung Function, Airway Responsiveness, and Symptoms in Children with Asthma. American Review of Respiratory Disease. https://doi.org/10.1164/ajrccm/146.3.547

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.